GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » Operating Cash Flow per Share

Fortress Biotech (FRA:CNB1) Operating Cash Flow per Share : €-12.46 (TTM As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Fortress Biotech Operating Cash Flow per Share?

Fortress Biotech's operating cash flow per share for the three months ended in Mar. 2024 was €-2.61. Fortress Biotech's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was €-12.46.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 3.20% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 8.70% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -8.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Fortress Biotech's Operating Cash Flow per Share or its related term are showing as below:

FRA:CNB1' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -63.5   Med: -0.4   Max: 32
Current: 3.2

During the past 13 years, Fortress Biotech's highest 3-Year average Operating Cash Flow per Share Growth Rate was 32.00% per year. The lowest was -63.50% per year. And the median was -0.40% per year.

FRA:CNB1's 3-Year OCF Growth Rate is ranked worse than
50.36% of 1233 companies
in the Biotechnology industry
Industry Median: 3.5 vs FRA:CNB1: 3.20

Fortress Biotech Operating Cash Flow per Share Historical Data

The historical data trend for Fortress Biotech's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech Operating Cash Flow per Share Chart

Fortress Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.43 -14.33 -18.94 -28.58 -15.96

Fortress Biotech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.94 -4.17 -2.10 -3.58 -2.61

Competitive Comparison of Fortress Biotech's Operating Cash Flow per Share

For the Biotechnology subindustry, Fortress Biotech's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Price-to-Operating-Cash-Flow falls into.



Fortress Biotech Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Fortress Biotech's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-117.582/7.36628
=-15.96

Fortress Biotech's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )=Cash Flow from Operations (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=-23.356/8.93759
=-2.61

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fortress Biotech Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Fortress Biotech (FRA:CNB1) Business Description

Traded in Other Exchanges
Address
1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Fortress Biotech (FRA:CNB1) Headlines

No Headlines